Interaksi Prednison

Prednison (Deltasone, Rayos), golongan kortikosteroid, memiliki 411 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 30 mayor, 294 moderat, 85 minor, dan 2 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Prednison (Deltasone, Rayos) adalah kortikosteroid, versi sintetis dari hormon yang dibuat kelenjar adrenal. Obat ini mengurangi peradangan dan meredam sistem imun. Obat ini digunakan untuk banyak kondisi, termasuk artritis, lupus, alergi berat, kekambuhan asma, penyakit kulit, beberapa kanker, dan kadar kortikosteroid alami yang rendah. Obat ini tersedia sebagai tablet, tablet lepas tunda, dan cairan, dan biasanya diminum bersama makanan satu sampai empat kali sehari atau dua hari sekali. Dosis berkisar dari 5 mg sampai 60 mg per hari bergantung pada kondisinya.

Interaksi dari label

Interaksi mayor (30)

  • Abirateronpenghambat CYP2D6Mayor

    At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (label Abirateron, Peringatan dan perhatian)

  • AdalimumabimunosupresanMayor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Adalimumab, Peringatan kotak hitam)

  • Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (label Aksitinib, Peringatan dan perhatian)

  • Arformoterolagonis beta-adrenergikMayor

    Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (label Arformoterol, Kontraindikasi)

  • Arsen trioksidaobat yang memperpanjang interval QTMayor

    If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (label Arsen trioksida, Peringatan kotak hitam)

  • AtazanavirantiretroviralMayor

    Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (label Atazanavir, Interaksi obat)

  • Barisitinibpenghambat JAKMayor

    Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Barisitinib, Peringatan kotak hitam)

  • Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (label Dosetaksel, Peringatan dan perhatian)

  • …(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (label Emtrisitabin, rilpivirin, dan tenofovir, Kontraindikasi)

  • EpinefrinsimpatomimetikMayor

    …Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (label Epinefrin, Interaksi obat)

  • EtanerseptimunosupresanMayor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Etanersept, Peringatan kotak hitam)

  • Formoterolagonis beta-adrenergikMayor

    Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (label Formoterol, Kontraindikasi)

  • FosamprenavirantiretroviralMayor

    Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (label Fosamprenavir, Interaksi obat)

  • InfliksimabimunosupresanMayor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Infliksimab, Peringatan kotak hitam)

  • Ketokonazolantijamur azolMayor

    Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (label Ketokonazol, Interaksi obat)

  • LovastatinstatinMayor

    Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (label Lovastatin, Kontraindikasi)

  • Mifepristonpenghambat CYP3A4Mayor

    WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (label Mifepriston, Peringatan kotak hitam)

  • Mitotanpenginduksi CYP3A4Mayor

    If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (label Mitotan, Peringatan kotak hitam)

  • Moeksiprilpenghambat ACEMayor

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (label Moeksipril, Peringatan)

  • NevirapinantiretroviralMayor

    Therefore, use of prednisone to prevent nevirapine-associated rash is not recommended. (label Nevirapin, Peringatan dan perhatian)

  • RilpivirinantiretroviralMayor

    Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (label Rilpivirin, Kontraindikasi)

  • Salmeterolagonis beta-adrenergikMayor

    WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (label Salmeterol, Peringatan kotak hitam)

  • SirolimusimunosupresanMayor

    In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (label Sirolimus, Peringatan dan perhatian)

  • Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (label Somatropin, Interaksi obat)

  • TofasitinibimunosupresanMayor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Tofasitinib, Peringatan kotak hitam)

  • TosilizumabimunosupresanMayor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Tosilizumab, Peringatan kotak hitam)

  • Trandolaprilpenghambat ACEMayor

    Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (label Trandolapril, Peringatan)

  • TretinoinretinoidMayor

    At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (label Tretinoin, Peringatan kotak hitam)

  • Umeklidinium dan vilanterolantikolinergikMayor

    • use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (label Umeklidinium dan vilanterol, Kontraindikasi)

  • UpadasitinibimunosupresanMayor

    Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (label Upadasitinib, Peringatan kotak hitam)

Interaksi moderat (294)

  • AfatinibModerat

    Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (label Afatinib, Peringatan dan perhatian)

  • AkarbosaantidiabetesModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • AklidiniumantikolinergikModerat

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (label Aklidinium, Interaksi obat)

  • AlbendazolModerat

    Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (label Albendazol, Peringatan dan perhatian)

  • AlemtuzumabimunosupresanModerat

    Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (label Alemtuzumab, Peringatan dan perhatian)

  • AlendronatbisfosfonatModerat

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (label Alendronat, Peringatan dan perhatian)

  • AliskirenantihipertensiModerat

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (label Aliskiren, Peringatan dan perhatian)

  • Alogliptinpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Alogliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • AlpelisibModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Amfoterisin BantijamurModerat

    Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (label Amfoterisin B, Interaksi obat)

  • AmiodaronantiaritmiaModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • ApiksabanantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Moderat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • ArgatrobanantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • Asam mefenamatOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Asam valproatantikonvulsanModerat

    Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (label Asam valproat, Interaksi obat)

  • Asam zoledronatbisfosfonatModerat

    A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (label Asam zoledronat, Peringatan dan perhatian)

  • AspirinOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Aspirin dan dipiridamolantiplateletModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • AzatioprinimunosupresanModerat

    In a detailed case report, 4 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. (label Azatioprin, Peringatan)

  • Azitromisinantibiotik makrolidaModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • BalsalazidsalisilatModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • BeklometasonkortikosteroidModerat

    Hypercorticism and Adrenal Suppression QVAR REDIHALER will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (label Beklometason, Peringatan dan perhatian)

  • Beksagliflozinpenghambat SGLT2Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Beladona dan opiumopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Beladona dan opium, Peringatan dan perhatian)

  • Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • • Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (label Benralizumab, Peringatan dan perhatian)

  • Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (label Biktegravir, emtrisitabin, dan tenofovir alafenamid, Interaksi obat)

  • Bismut subsalisilatsalisilatModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • BivalirudinantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Moderat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • BudesonidkortikosteroidModerat

    Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with PULMICORT FLEXHALER. (label Budesonid, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (label Budesonid dan formoterol, Peringatan dan perhatian)

  • BuprenorfinopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Buprenorfin, Peringatan dan perhatian)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Buprenorfin dan nalokson, Peringatan dan perhatian)

  • BupropionantidepresanModerat

    …risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (label Bupropion, Peringatan dan perhatian)

  • CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (label Prednison, Interaksi obat)

  • CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (label Prednison, Interaksi obat)

  • ButorfanolopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Butorfanol, Peringatan)

  • DabigatranantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Dapagliflozinpenghambat SGLT2Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Dapagliflozin dan metforminpenghambat SGLT2Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • DaptomisinantibiotikModerat

    Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (label Daptomisin, Peringatan dan perhatian)

  • DarunavirantiretroviralModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Deferasirokssuplemen zat besiModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • DeksametasonkortikosteroidModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • DenosumabModerat

    Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (label Denosumab, Peringatan dan perhatian)

  • Desogestrel dan etinilestradiolkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • DiflunisalOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Digoksinglikosida digitalisModerat

    Digitalis Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia. (label Prednison, Interaksi obat)

  • DiklofenakOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • DisikloverinantikolinergikModerat

    Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (label Disikloverin, Interaksi obat)

  • …treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase. (label Doksorubisin, Interaksi obat)

  • DolutegravirantiretroviralModerat

    …following drugs can be coadministered with dolutegravir without a dose adjustment: atazanavir/ritonavir, darunavir/ritonavir, elbasvir/grazoprevir, methadone, midazolam, omeprazole, oral contraceptives containing norgestimate and ethinyl estradiol, prednisone, rifabutin, rilpivirine, sofosbuvir/velpatasvir, and tenofovir [see Clinical Pharmacology ( 12.3 )] . (label Dolutegravir, Interaksi obat)

  • DronedaronantiaritmiaModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Drospirenon dan etinilestradiolkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Dulaglutidagonis reseptor GLP-1Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • DupilumabModerat

    Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (label Dupilumab, Peringatan dan perhatian)

  • EdoksabanantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • EfavirenzantiretroviralModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • EfedrinsimpatomimetikModerat

    CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (label Prednison, Interaksi obat)

  • Eksenatidagonis reseptor GLP-1Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (label Eleksakaftor, tezakaftor, dan ivakaftor, Peringatan dan perhatian)

  • CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Empagliflozinpenghambat SGLT2Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Empagliflozin dan metforminpenghambat SGLT2Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • EnoksaparinantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Eritromisinantibiotik makrolidaModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • ErlotinibModerat

    Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (label Erlotinib, Peringatan dan perhatian)

  • EslikarbazepinantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • EstradiolestrogenModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Estradiol dan dienogestkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Estrogen terkonjugasiestrogenModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • EtodolakOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • EtravirinantiretroviralModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • EverolimusimunosupresanModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • FenilefrindekongestanModerat

    Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (label Fenilefrin, Interaksi obat)

  • FenitoinantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • FenobarbitalbarbituratModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (label Prednison, Interaksi obat)

  • FenoprofenOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • FentanilopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Fentanil, Peringatan dan perhatian)

  • Fentermin dan topiramatstimulan SSPModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • Fidaksomisinantibiotik makrolidaModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • FingolimodimunosupresanModerat

    In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (label Fingolimod, Peringatan dan perhatian)

  • Flukonazolantijamur azolModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • FlunisolidkortikosteroidModerat

    The use of flunisolide with alternate-day prednisone systemic treatment could increase the likelihood of HPA suppression compared to a therapeutic dose of either one alone. (label Flunisolid, Peringatan)

  • FluosinonidkortikosteroidModerat

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (label Fluosinonid, Peringatan dan perhatian)

  • FlurbiprofenOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • FlutikasonkortikosteroidModerat

    Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with Fluticasone Propionate DISKUS. (label Flutikason, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    Hypercorticism and Adrenal Suppression Fluticasone propionate, a component of Fluticasone Propionate/Salmeterol MDPI, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (label Flutikason dan salmeterol, Peringatan dan perhatian)

  • FondaparinuksantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Moderat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • FosfenitoinantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • FulvestrantestrogenModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • GlibenklamidsulfonilureaModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Glibenklamid dan metforminsulfonilureaModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • GlimepiridsulfonilureaModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • GlipizidsulfonilureaModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Glipizid dan metforminsulfonilureaModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (label Gliserol fenilbutirat, Interaksi obat)

  • GriseofulvinantijamurModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • HalobetasolkortikosteroidModerat

    Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (label Halobetasol, Peringatan dan perhatian)

  • HaloperidolantipsikotikModerat

    Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (label Haloperidol, Interaksi obat)

  • HeparinantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • HidralazinvasodilatorModerat

    Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (label Hidralazin, Peringatan)

  • HidrokodonopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Hidrokodon, Peringatan dan perhatian)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Hidrokodon dan homatropin, Peringatan dan perhatian)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Hidrokodon dan klorfeniramin, Peringatan dan perhatian)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Hidrokodon dan parasetamol, Peringatan)

  • HidromorfonopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Hidromorfon, Peringatan dan perhatian)

  • IbandronatbisfosfonatModerat

    …osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (label Ibandronat, Peringatan dan perhatian)

  • IbuprofenOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Imatinibpenghambat CYP3A4Moderat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • IndometasinOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Insulin aspartinsulinModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Insulin degludekinsulinModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Insulin detemirinsulinModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Insulin glargininsulinModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Insulin lisproinsulinModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • IsoniazidantibiotikModerat

    Antitubercular Drugs Serum concentrations of isoniazid may be decreased. (label Prednison, Interaksi obat)

  • Itrakonazolantijamur azolModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Moderat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • IvermektinModerat

    Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (label Ivermektin, Peringatan)

  • Kanagliflozinpenghambat SGLT2Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • KarbamazepinantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • KetoprofenOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • KetorolakOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • KladribinantimetabolitModerat

    Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (label Kladribin, Interaksi obat)

  • Klaritromisinantibiotik makrolidaModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • KlobazambenzodiazepinModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • KodeinopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Kodein, Peringatan dan perhatian)

  • Kokainanestetik lokalModerat

    Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (label Kokain, Interaksi obat)

  • Kolestiraminsekuestran asam empeduModerat

    Cholestyramine Cholestyramine may increase the clearance of corticosteroids. (label Prednison, Interaksi obat)

  • LenakapavirantiretroviralModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • LevofloksasinfluorokuinolonModerat

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (label Levofloksasin, Peringatan dan perhatian)

  • LevonorgestrelprogestinModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Levonorgestrel dan etinilestradiolkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • LevorfanolopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Levorfanol, Peringatan)

  • Levosalbutamolagonis beta-adrenergikModerat

    If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (label Levosalbutamol, Peringatan dan perhatian)

  • Levotiroksinhormon tiroidModerat

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (label Prednison, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (label Prednison, Peringatan dan perhatian)

  • Linagliptinpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Linagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Liotironinhormon tiroidModerat

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (label Prednison, Peringatan dan perhatian)

  • Liraglutidagonis reseptor GLP-1Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (label Lisinopril dan hidroklorotiazid, Peringatan)

  • Lopinavir dan ritonavirantiretroviralModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Moderat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (label Margetuksimab, Peringatan dan perhatian)

  • MedroksiprogesteronprogestinModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • MegestrolprogestinModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • MeloksikamOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Decrease corticosteroids gradually, if appropriate. (label Mepolizumab, Peringatan dan perhatian)

  • MesalazinsalisilatModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • MetadonopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Metadon, Peringatan dan perhatian)

  • Metazolamidpenghambat karbonat anhidraseModerat

    Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (label Metazolamid, Interaksi obat)

  • MetforminbiguanidModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • MetildopaantihipertensiModerat

    If not, corticosteroids may be given and other causes of anemia should be considered. (label Metildopa, Peringatan)

  • MetiltestosteronandrogenModerat

    Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (label Metiltestosteron, Peringatan)

  • MetiraponModerat

    This can be corrected by giving appropriate doses of corticosteroids. (label Metirapon, Peringatan dan perhatian)

  • MetoheksitalbarbituratModerat

    CYP 3A4 Inducers (e.g., Barbiturates, Phenytoin, Carbamazepine, and Rifampin) Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (label Prednison, Interaksi obat)

  • Metolazondiuretik tiazidModerat

    Corticosteroids Or ACTH May increase the risk of hypokalemia and increase salt and water retention. (label Metolazon, Interaksi obat)

  • MetotreksatimunosupresanModerat

    NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (label Metotreksat, Interaksi obat)

  • MiglitolantidiabetesModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Mirabegronagonis beta-adrenergikModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Moderat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (label Mitoksantron, Peringatan)

  • Modafinilstimulan SSPModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • MoksifloksasinfluorokuinolonModerat

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (label Moksifloksasin, Peringatan dan perhatian)

  • MometasonkortikosteroidModerat

    Hypercorticism and Adrenal Suppression ASMANEX HFA will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. (label Mometason, Peringatan dan perhatian)

  • Montelukastantagonis reseptor leukotrienModerat

    Inhaled corticosteroid may be reduced gradually. (label Montelukast, Peringatan dan perhatian)

  • MorfinopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Morfin, Peringatan dan perhatian)

  • NabumetonOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Nafsilinantibiotik penisilinModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • NalbufinopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Nalbufin, Peringatan)

  • Naltrekson dan bupropionantagonis opioidModerat

    …hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (label Naltrekson dan bupropion, Peringatan dan perhatian)

  • NaproksenOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NatalizumabimunosupresanModerat

    In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (label Natalizumab, Peringatan dan perhatian)

  • NateglinidmeglitinidModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (label Natrium fenilasetat dan natrium benzoat, Interaksi obat)

  • Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (label Natrium fenilbutirat, Interaksi obat)

  • NefazodonantidepresanModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • NintedanibModerat

    Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (label Nintedanib, Peringatan dan perhatian)

  • CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • NoretisteronprogestinModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Noretisteron dan etinilestradiolkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Norgestimat dan etinilestradiolkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • Norgestrel dan etinilestradiolkontrasepsi oralModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • OfloksasinfluorokuinolonModerat

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (label Ofloksasin, Peringatan)

  • OkrelizumabimunosupresanModerat

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (label Okrelizumab, Peringatan dan perhatian)

  • OksaprozinOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • OksikodonopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Oksikodon, Peringatan dan perhatian)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Oksikodon dan parasetamol, Peringatan dan perhatian)

  • OksimorfonopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Oksimorfon, Peringatan dan perhatian)

  • OkskarbazepinantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • OliseridinopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Oliseridin, Peringatan dan perhatian)

  • OmalizumabModerat

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (label Omalizumab, Peringatan dan perhatian)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Moderat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • PamidronatbisfosfonatModerat

    Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (label Pamidronat, Peringatan dan perhatian)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Parasetamol dan kodein, Peringatan)

  • PasireotidModerat

    If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (label Pasireotid, Peringatan dan perhatian)

  • Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (label Penisilamin, Peringatan)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Pentazosin dan nalokson, Peringatan)

  • PerampanelantikonvulsanModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • PetidinopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Petidin, Peringatan dan perhatian)

  • PioglitazontiazolidindionModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Pioglitazon dan glimepiridtiazolidindionModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Pioglitazon dan metformintiazolidindionModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • PiroksikamOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • PonesimodimunosupresanModerat

    Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (label Ponesimod, Peringatan dan perhatian)

  • Posakonazolantijamur azolModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • PrednisolonkortikosteroidModerat

    Published animal studies show prednisolone to be teratogenic in rats, rabbits, hamsters, and mice with increased incidence of cleft palate in offspring. (label Prednison, Peringatan dan perhatian)

  • PrimidonantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • ProgesteronprogestinModerat

    Estrogens, Including Oral Contraceptives Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. (label Prednison, Interaksi obat)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Prometazin dan kodein, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidModerat

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (label Prednison, Peringatan dan perhatian)

  • Propofoldepresan SSPModerat

    The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (label Propofol, Peringatan dan perhatian)

  • Ranolazinobat yang memperpanjang interval QTModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • RepaglinidmeglitinidModerat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • RifabutinantibiotikModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • RifampisinantibiotikModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • RifapentinantibiotikModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • RisedronatbisfosfonatModerat

    …the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (label Risedronat, Peringatan dan perhatian)

  • RitonavirantiretroviralModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • RivaroksabanantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Rokuroniumpenyekat neuromuskularModerat

    Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (label Rokuronium, Peringatan dan perhatian)

  • Saksagliptinpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Saksagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Salbutamolagonis beta-adrenergikModerat

    If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (label Salbutamol, Peringatan dan perhatian)

  • SalsalatOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • SefoksitinsefalosporinModerat

    High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (label Sefoksitin, Peringatan dan perhatian)

  • SelekoksibOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Semaglutidagonis reseptor GLP-1Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • SenobamatantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • SiklesonidkortikosteroidModerat

    Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during ALVESCO therapy [see Dosage and Administration ( 2 )] . (label Siklesonid, Peringatan dan perhatian)

  • SiklosporinimunosupresanModerat

    Cyclosporine: Increase in activity of both, cyclosporine and corticosteroid when administered concurrently. (label Prednison, Interaksi obat)

  • Simetidinpenghambat H2Moderat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • SiprofloksasinfluorokuinolonModerat

    The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (label Siprofloksasin, Peringatan dan perhatian)

  • Sitagliptinpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • Sitagliptin dan metforminpenghambat DPP-4Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • SitarabinantimetabolitModerat

    Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (label Sitarabin, Interaksi obat)

  • Suksinilkolinpenyekat neuromuskularModerat

    The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (label Suksinilkolin, Interaksi obat)

  • SulfasalazinsulfonamidaModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • SulindakOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • Suvoreksantsedatif-hipnotikModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Moderat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • TakrolimusimunosupresanModerat

    Mild or Moderate CYP3A Inducers Methylprednisolone, prednisone May decrease tacrolimus whole blood trough concentrations. (label Takrolimus, Interaksi obat)

  • TapentadolopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Tapentadol, Peringatan dan perhatian)

  • Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (label Temozolomid, Peringatan dan perhatian)

  • If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (label Temsirolimus, Peringatan dan perhatian)

  • TeofilinmetilxantinModerat

    Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (label Teofilin, Peringatan)

  • Terbutalinagonis beta-adrenergikModerat

    If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (label Terbutalin, Peringatan)

  • Teriparatidhormon tiroidModerat

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (label Prednison, Peringatan dan perhatian)

  • Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (label Tesamorelin, Interaksi obat)

  • TestosteronandrogenModerat

    Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (label Testosteron, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    Changes in thyroid status of the patient may necessitate adjustment in dosage. (label Prednison, Peringatan dan perhatian)

  • TikagrelorantiplateletModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • TiotropiumantikolinergikModerat

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (label Tiotropium, Interaksi obat)

  • Tirzepatidagonis reseptor GLP-1Moderat

    Antidiabetic agents: May increase blood glucose concentrations. (label Prednison, Interaksi obat)

  • TolmetinOAINSModerat

    NSAIDs including aspirin and salicylates: Increased risk of gastrointestinal side effects. (label Prednison, Interaksi obat)

  • TopiramatantikonvulsanModerat

    CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (label Prednison, Interaksi obat)

  • Torasemiddiuretik loopModerat

    Corticosteroids and ACTH: Increased risk of hypokalemia. (label Torasemid, Interaksi obat)

  • TramadolopioidModerat

    If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Tramadol, Peringatan dan perhatian)

  • If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (label Tramadol dan parasetamol, Peringatan dan perhatian)

  • Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (label Trastuzumab, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Other Considerations Concurrent use of hydrochlorothiazide with amphotericin B or corticosteroids or corticotropin (ACTH) may intensify electrolyte imbalance, particularly hypokalemia, although the presence of triamterene minimizes the hypokalemic effect. (label Triamteren dan hidroklorotiazid, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • Vorikonazolantijamur azolModerat

    CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (label Prednison, Interaksi obat)

  • WarfarinantikoagulanModerat

    Anticoagulant agents: May enhance or diminish anticoagulant effects. (label Prednison, Interaksi obat)

  • Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (label Zenokutuzumab, Peringatan dan perhatian)

Penyebutan minor (85)

  • If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (label Alteplase, Peringatan dan perhatian)

  • Amfetaminstimulan SSPMinor

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (label Amfetamin, Interaksi obat)

  • Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (label Amfetamin dan dekstroamfetamin, Interaksi obat)

  • AmikasinaminoglikosidaMinor

    Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (label Amikasin, Peringatan dan perhatian)

  • Amiloriddiuretik hemat kaliumMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Ampisilinantibiotik penisilinMinor

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (label Ampisilin, Peringatan)

  • Asam bempedoatpenghambat OATP1B1Minor

    Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (label Asam bempedoat, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Asetazolamidpenghambat karbonat anhidraseMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Atenolol dan klortalidonpenyekat betaMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Benzilpenisilin (penisilin G)antibiotik penisilinMinor

    Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (label Benzilpenisilin (penisilin G), Peringatan)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (label Bevasizumab, Peringatan dan perhatian)

  • Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • …50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (label Bortezomib, Peringatan dan perhatian)

  • Bumetaniddiuretik loopMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (label Busulfan, Peringatan)

  • Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Dekstroamfetaminstimulan SSPMinor

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (label Dekstroamfetamin, Interaksi obat)

  • Donepezilpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • Droperidolantagonis dopaminMinor

    These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (label Droperidol, Interaksi obat)

  • Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Eplerenonantagonis aldosteronMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Fenoksimetilpenisilin (penisilin V)antibiotik penisilinMinor

    OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (label Fenoksimetilpenisilin (penisilin V), Peringatan)

  • Fisostigminpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • FludarabinantimetabolitMinor

    Steroids may or may not be effective in controlling these hemolytic episodes. (label Fludarabin, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidMinor

    Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (label Prednison, Peringatan dan perhatian)

  • FluoksetinSSRIMinor

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (label Fluoksetin, Peringatan dan perhatian)

  • Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Furosemiddiuretik loopMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Galantaminpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (label Glukagon, Peringatan dan perhatian)

  • GuselkumabimunosupresanMinor

    TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (label Guselkumab, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • HidrokortisonkortikosteroidMinor

    Amphotericin B Injection There have been cases reported in which concomitant use of Amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure [see Drug Interactions (7.14) ] . (label Prednison, Interaksi obat)

  • Indapamiddiuretik tiazidMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • IpratropiumantikolinergikMinor

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (label Ipratropium, Interaksi obat)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Kalsitriolanalog vitamin DMinor

    Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (label Kalsitriol, Interaksi obat)

  • Kanabidiol (obat resep)antikonvulsanMinor

    Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (label Kanabidiol (obat resep), Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • KlofarabinantimetabolitMinor

    The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (label Klofarabin, Peringatan dan perhatian)

  • Klomifenmodulator reseptor estrogen selektifMinor

    Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (label Klomifen, Peringatan)

  • Klorotiaziddiuretik tiazidMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Klortalidondiuretik tiazidMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (label Kortikotropin, Peringatan dan perhatian)

  • Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • KuininantimalariaMinor

    Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (label Kuinin, Interaksi obat)

  • Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (label Lenalidomid, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (label Melfalan, Peringatan)

  • Memantin dan donepezilpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • Metamfetaminstimulan SSPMinor

    Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (label Metamfetamin, Interaksi obat)

  • Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Midodrinagonis alfa-adrenergikMinor

    Midodrine hydrochloride has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. (label Midodrin, Interaksi obat)

  • Naltreksonantagonis opioidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (label Naltrekson, Peringatan dan perhatian)

  • Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (label Natrium zirkonium siklosilikat, Interaksi obat)

  • Neostigminpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • Nimodipinpenghambat kanal kalsium dihidropiridinMinor

    Moderate and weak CYP3A4 inducers include, for example: amprenavir, aprepitant, armodafinil, bosentan, efavirnenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib. (label Nimodipin, Interaksi obat)

  • Oksasilinantibiotik penisilinMinor

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (label Oksasilin, Peringatan)

  • Olanzapin dan fluoksetinantipsikotikMinor

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Pilokarpinagonis kolinergikMinor

    …performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (label Pilokarpin, Interaksi obat)

  • Piridostigminpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • Raloksifenmodulator reseptor estrogen selektifMinor

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (label Raloksifen, Interaksi obat)

  • RituksimabimunosupresanMinor

    Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (label Rituksimab, Peringatan dan perhatian)

  • Rivastigminpenghambat kolinesteraseMinor

    Anticholinesterase Agents Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. (label Prednison, Interaksi obat)

  • SefadroksilsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefadroksil, Peringatan dan perhatian)

  • SefaklorsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefaklor, Peringatan)

  • SefdinirsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefdinir, Peringatan)

  • SefotetansefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefotetan, Peringatan)

  • SefprozilsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefprozil, Peringatan)

  • SeftazidimsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Seftazidim, Peringatan)

  • SeftriaksonsefalosporinMinor

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (label Seftriakson, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (label Tenekteplase, Peringatan dan perhatian)

  • TobramisinaminoglikosidaMinor

    In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (label Tobramisin, Interaksi obat)

  • Triamterendiuretik hemat kaliumMinor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • UstekinumabimunosupresanMinor

    Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (label Ustekinumab, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Potassium-Depleting Agents (e.g., Diuretics, Amphotericin B) When corticosteroids are administered concomitantly with potassium-depleting agents, patients should be observed closely for development of hypokalemia. (label Prednison, Interaksi obat)

  • Vitamin DVitamin dan mineralMinor

    Kortikosteroid seperti prednison mengurangi penyerapan kalsium dan mengganggu metabolisme vitamin D, sehingga ikut menyebabkan pengeroposan tulang. (NIH Office of Dietary Supplements, Vitamin D)

  • ZiprasidonantipsikotikMinor

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (label Ziprasidon, Peringatan dan perhatian)

Tidak ada interaksi bermakna yang dilaporkan (2)

  • AminofilinmetilxantinTanpa interaksi

    …influenza vaccine ketoconazole lomefloxacin mebendazole medroxyprogesterone methylprednisolone metronidazole metoprolol nadolol nifedipine nizatidine norfloxacin ofloxacin omeprazole prednisone, prednisolone ranitidine rifabutin roxithromycin sorbitol (purgative doses do not inhibit theophylline absorption) sucralfate terbutaline, systemic terfenadine tetracycline… (label Aminofilin, Interaksi obat)

  • Zileutonpenghambat CYP1A2Tanpa interaksi

    Other Concomitant Drug Therapy Drug-drug interaction studies conducted in healthy subjects between zileuton immediate-release tablets and prednisone and ethinyl estradiol (oral contraceptive), drugs known to be metabolized by the CYP3A4 isoenzyme, have shown no significant interaction. (label Zileuton, Interaksi obat)

Periksa Prednison terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.